What drove IHL.AX stock lower today?

Heavy intraday selling on 24 Feb 2026 pushed IHL.AX stock to A$0.041 on **61,360,016** shares. Traders cite pipeline news sensitivity and speculative selling in small healthcare caps as primary drivers.

What is Meyka AI’s forecast for IHL.AX stock?

Meyka AI's forecast model projects a base-case **A$0.090**, implying **119.51%** upside from the current **A$0.041**. Forecasts are model-based projections and not guarantees.

Is IHL.AX stock a buy for long-term investors?

IHL.AX stock suits risk-tolerant investors who accept clinical and financing risk. Meyka AI gives a Hold grade (B) based on growth metrics and sector comparison; do further due diligence before long-term exposure.

What catalysts should traders watch for IHL.AX stock?

Watch clinical trial readouts, licensing or partnership announcements, and capital raising statements. Any update on Phase IIa programs can move the stock materially.

AU Stocks

Intraday 24 Feb 2026: IHL.AX stock down 10.87% to A$0.041 on 61.36M volume: active traders eye catalysts

ByDanny Kontos February 24, 2026

IHL.AX stock opened weaker and traded down 10.87% intraday to A$0.041 on 61,360,016 shares as of this intraday update on 24 Feb 2026. The move comes after a gap lower from an open of A$0.047, with a day high at A$0.051 and the session low at A$0.041. Traders are watching clinical news and cash runway signals given the company’s small market cap of A$14,255,927.00 and high relative volume. We examine what drove the flow, the fundamentals, chart setup, and near-term price scenarios